Phenotypes Associated with This Genotype

Genotype
MGI:5581813

• Allelic Composition: Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor⁺; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

decreased fasting circulating glucose level ( J:210493 )

• in tamoxifen-treated mice

• however, induced hypoglycemia is transient

increased circulating insulin level ( J:210493 )

• in tamoxifen-treated mice

increased oxygen consumption ( J:210493 )

• in tamoxifen-treated mice

endocrine/exocrine glands

abnormal pancreatic beta cell physiology ( J:210493 )

• increased beta cell apoptosis and reduced proliferation in tamoxifen-treated mice

• beta cells from tamoxifen-treated mice exhibit glucotoxicity including increased expression of ER and oxidative stress markers compared to in control cells

• however, GFP- beta cells exhibit increased proliferation and mice treated with a selective inhibitor of calcineurin (tacrolimus; FK-506) or a GLP-1 receptor agonist (liraglutide) exhibit reduced beta cell apoptosis and dysfunction

decreased pancreatic beta cell proliferation ( J:210493 )

• reduced proliferation in tamoxifen-treated mice

• however, GFP- beta cells exhibit increased proliferation

cellular

decreased pancreatic beta cell proliferation ( J:210493 )

• reduced proliferation in tamoxifen-treated mice

• however, GFP- beta cells exhibit increased proliferation